Rapid urine LAM test result during 6 months of anti-TB treatment
| Baseline (N=90) | 2-Month follow-up (N=73) | p Value (baseline vs 2 months) | 6-Month follow-up (N=50) | p Value (baseline vs 6 months) | |
|---|---|---|---|---|---|
| Rapid urine LAM positive | N (%) | N (%) | N (%) | ||
| All participants | 29 (32.2) | 12 (16.4)* | 0.0009 | 5 (10.0)† | 0.004 |
| HIV+ | 28 (34.1) | 12 (17.6) | 0.002 | 5 (10.6) | 0.007 |
| HIV+ and CD4 ≥100/mm3 | 14 (25.5) | 4 (8.2) | 0.01 | 3 (8.6) | 0.11 |
| HIV+ and CD4 <100/mm3 | 14 (51.9) | 8 (42.1) | 0.25 | 2 (16.7) | 0.06 |
| Rapid urine LAM grade | Mean±SD | Mean±SD | Mean±SD | ||
| All participants | 0.7±1.3 | 0.5±1.2 | 0.005 | 0.2±0.7 | 0.006 |
| HIV+ | 0.8±1.4 | 0.5±1.3 | 0.007 | 0.2±0.8 | 0.008 |
| HIV+ and CD4 ≥100/mm3 | 0.5±1.0 | 0.2±0.8 | 0.007 | 0.1±0.3 | 0.04 |
| HIV+ and CD4 <100/mm3 | 1.3±1.8 | 1.3±1.9‡ | 0.31 | 0.5±1.4 | 0.08 |
*1 culture-negative participant with negative baseline rapid urinary LAM became positive at the 2-month follow-up visit.
†2 culture-positive participants with negative baseline rapid urinary LAM became positive at the 6-month follow-up visit.
‡1 culture-positive participant with 1+ grade at baseline rapid urinary LAM became 3+ at the 2 month follow-up visit; this participant died during the study.
LAM, lipoarabinomannan; TB, tuberculosis.